Huaising C Ko1, Shuai Chen2, Aaron M Wieland3, Menggang Yu2, Andrew M Baschnagel1, Gregory K Hartig3, Paul M Harari1, Matthew E Witek1. 1. Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 2. Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 3. Department of Surgery, Division of Otolaryngology and Head and Neck Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Abstract
BACKGROUND: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. METHODS: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. RESULTS: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P = .06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P < .05). CONCLUSION: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30% independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.
BACKGROUND: There is a paucity of data regarding head and neck squamous cell carcinomas (HNSCCs) and N3 nodal disease. METHODS: Retrospective analysis of patients with N3 HNSCC identified in the National Cancer Database (NCDB) was performed. RESULTS: We identified 4867 patients with N3 HNSCC treated with primary surgery or chemoradiotherapy (CRT). Propensity-adjusted median survival was 54.2 and 44.8 months for surgery and CRT, respectively (P = .06). Oropharyngeal primary subsite demonstrated a survival advantage with surgery versus CRT with propensity-adjusted median survivals of 86.0 and 61.9 months, respectively (P < .05). CONCLUSION: Management of N3 HNSCC relies largely on CRT. Patients with N3 nodal disease with nonoropharyngeal primary tumors exhibit 5-year overall survival approaching 30% independent of initial treatment modality. Patients with oropharyngeal primaries exhibit improved outcomes with surgery largely influenced by the human papillomavirus (HPV)-negative subset. These data represent the most comprehensive analysis of N3 HNSCC outcomes and serves as a foundation for future research and clinical management.
Authors: David G Pfister; Sharon Spencer; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; A Dimitrios Colevas; Frank Dunphy; David W Eisele; Jill Gilbert; Maura L Gillison; Robert I Haddad; Bruce H Haughey; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Merrill S Kies; William M Lydiatt; Ellie Maghami; Renato Martins; Thomas McCaffrey; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; Cristina P Rodriguez; Sandeep Samant; David E Schuller; Jatin P Shah; Randal S Weber; Gregory T Wolf; Frank Worden; Sue S Yom; Nicole R McMillian; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2014-10 Impact factor: 11.908
Authors: Ezra E W Cohen; Theodore G Karrison; Masha Kocherginsky; Jeffrey Mueller; Robyn Egan; Chao H Huang; Bruce E Brockstein; Mark B Agulnik; Bharat B Mittal; Furhan Yunus; Sandeep Samant; Luis E Raez; Ranee Mehra; Priya Kumar; Frank Ondrey; Patrice Marchand; Bettina Braegas; Tanguy Y Seiwert; Victoria M Villaflor; Daniel J Haraf; Everett E Vokes Journal: J Clin Oncol Date: 2014-07-21 Impact factor: 44.544
Authors: Surbhi Grover; Samuel Swisher-McClure; Nandita Mitra; Jiaqi Li; Roger B Cohen; Peter H Ahn; John N Lukens; Ara A Chalian; Gregory S Weinstein; Bert W O'Malley; Alexander Lin Journal: Int J Radiat Oncol Biol Phys Date: 2015-07-01 Impact factor: 7.038
Authors: Jessica K Smyth; Allison M Deal; Benjamin Huang; Mark Weissler; Adam Zanation; Carol Shores Journal: Laryngoscope Date: 2011-09 Impact factor: 3.325
Authors: Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2014-12-08 Impact factor: 44.544
Authors: Ari Ballonoff; David Raben; Kyle E Rusthoven; Michael Bassetti; Madeleine Kane; John I Song; Changhu Chen Journal: Laryngoscope Date: 2008-06 Impact factor: 3.325
Authors: Hugh A J Kim; Peter Y F Zeng; Alana Sorgini; Mushfiq H Shaikh; Halema Khan; Danielle MacNeil; Mohammed I Khan; Adrian Mendez; John Yoo; Kevin Fung; Pencilla Lang; David A Palma; Joe S Mymryk; John W Barrett; Krupal B Patel; Paul C Boutros; Anthony C Nichols Journal: Head Neck Date: 2022-02-21 Impact factor: 3.821